All In Biotech

Drug Trial Radar · NCT04370704

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

61

Actual

Start

Jul 27, 2020

Primary completion

Aug 25, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
May 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.

Conditions

  • Melanoma

Interventions

  • INCAGN02385Drug

    INCAGN02385 administered intravenously

  • INCAGN02390Drug

    INCAGN02390 administered intravenously

  • INCMGA00012.Drug

    INCMGA00012 administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Time frame: up to 1148 days
  2. Phase 1: Number of Participants With Any ≥Grade 3 TEAETime frame: up to 1148 days

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • H Lee Moffitt Cancer Center and Research

    Tampa, Florida

  • University of Iowa

    Iowa City, Iowa

  • Cancer Center For Blood Disorders A Division of American Oncology Partners P.A

    Bethesda, Maryland

  • Washington University

    St Louis, Missouri

  • John Theurer Cancer Center, Hackensack University Medical Center

    Hackensack, New Jersey

  • Nyu Langone Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • Carolina Bio Oncology

    Huntersville, North Carolina

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • University of Washington-Seattle Cancer Care Alliance

    Seattle, Washington

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia

  • Greenslopes Private Hospital

    Brisbane, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • One Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.